Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ALLIANCE PHARMA PLC AGM Information 2019

May 23, 2019

7478_dva_2019-05-23_589abf20-1a6f-4bb5-ad31-5350774212e0.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9998Z

Alliance Pharma PLC

23 May 2019

23 May 2019

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of 2019 AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that at the Annual General Meeting of the Company held this morning, all resolutions as set out in the Notice of Meeting dated 16 April 2019 were duly passed on a show of hands. 

For further information:

Alliance Pharma plc                                                                                          + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                            + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited                                                                                  + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield

Corporate Broking: James Black

Investec Bank plc                                                                                              +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGPGUQPAUPBUBW